GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » ROE % Adjusted to Book Value

Cellectis (Cellectis) ROE % Adjusted to Book Value

: -70.43% (As of Sep. 2023)
View and export this data going back to 2015. Start your Free Trial

Cellectis's ROE % for the quarter that ended in Sep. 2023 was -80.99%. Cellectis's PB Ratio for the quarter that ended in Sep. 2023 was 1.15. Cellectis's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 was -70.43%.


Cellectis ROE % Adjusted to Book Value Historical Data

The historical data trend for Cellectis's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.50 -12.20 -6.63 -27.08 -77.25

Cellectis Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Adjusted to Book Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -98.07 -104.01 -110.47 -35.85 -70.43

Competitive Comparison

For the Biotechnology subindustry, Cellectis's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis ROE % Adjusted to Book Value Distribution

For the Biotechnology industry and Healthcare sector, Cellectis's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cellectis's ROE % Adjusted to Book Value falls into.



Cellectis ROE % Adjusted to Book Value Calculation

Cellectis's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-62.57% / 0.81
=-77.25%

Cellectis's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-80.99% / 1.15
=-70.43%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellectis ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Cellectis's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis (Cellectis) Business Description

Industry
Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Cellectis (Cellectis) Headlines

From GuruFocus

Cellectis Announces Launch of Follow-On Offering

By Stock market mentor Stock market mentor 02-02-2023